Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2019

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RESORCE
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 09 Apr 2019 Planned End Date changed from 31 Dec 2019 to 27 Sep 2019.
    • 24 Feb 2019 Planned End Date changed from 31 May 2019 to 31 Dec 2019.
    • 06 Feb 2019 A preplanned, retrospective biomarker analysis results (n=573) were published in the Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top